BioCentury

7:00 AM GMT, Sep 27, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Linagliptin: Phase III data

In a double-blind Phase III trial in 245 patients with inadequately controlled Type II diabetes, once-daily 5 mg oral linagliptin as an add-on to sulfonylurea met the

Read the full 276 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.